La Commissione Europea approva Crizotinib per il trattamento del NSCLC positivo a ROS1

The European Commission (EC) has approved crizotinib (Xalkori) as a treatment for patients with advanced ROS1-positive non–small cell lung cancer (NSCLC), based on an improvement in objective response rate (ORR) in a phase I study.Findings from the single-arm 50-patient study that led to the approval were published in The New England Journal of Medicine in 2014. In this study, crizotinib showed an ORR of 66% with a median duration of response of 18.3 months by independent review.The approval decision followed a positive recommendation from the Committee for Medicinal Products for Human … (leggi tutto)